Last reviewed · How we verify
MSB0010718C
MSB0010718C is a therapeutic cancer vaccine designed to activate the immune system against tumor-associated antigens.
MSB0010718C is a therapeutic cancer vaccine designed to activate the immune system against tumor-associated antigens. Used for Melanoma (in combination with checkpoint inhibitors), Non-small cell lung cancer (in combination with checkpoint inhibitors).
At a glance
| Generic name | MSB0010718C |
|---|---|
| Also known as | Avelumab |
| Sponsor | Istituto Oncologico Veneto IRCCS |
| Drug class | Therapeutic cancer vaccine |
| Target | Patient-specific tumor neoantigens |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MSB0010718C is an individualized neoantigen-based immunotherapy that combines personalized tumor mutation profiling with immunogenic peptide sequences to stimulate CD8+ T-cell responses against patient-specific cancer mutations. The vaccine is typically administered in combination with checkpoint inhibitors to enhance anti-tumor immunity. This approach aims to generate durable, personalized immune responses targeting the unique mutational landscape of each patient's tumor.
Approved indications
- Melanoma (in combination with checkpoint inhibitors)
- Non-small cell lung cancer (in combination with checkpoint inhibitors)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Chills
Key clinical trials
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Targeted Therapy and Avelumab in Merkel Cell Carcinoma (PHASE1, PHASE2)
- A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy (PHASE2)
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (PHASE1, PHASE2)
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (PHASE3)
- Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial (PHASE2)
- Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (PHASE1, PHASE2)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSB0010718C CI brief — competitive landscape report
- MSB0010718C updates RSS · CI watch RSS
- Istituto Oncologico Veneto IRCCS portfolio CI